<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OnYtMd8A4SohbjnvudvR-qko4ZAfy9-ImY9q-o0H8flnYAA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OnYtMd8A4SohbjnvudvR-qko4ZAfy9-ImY9q-o0H8flnYAA/641"/>
This report (chinatimes.net.cn) reporter Zhao Wenjuan and Yu Na reported from Beijing
On March 16, Blue Sail Medical issued an announcement. The actual controller Li Zhenping's entity intends to lend 350 million yuan to the listed company for a term of one year to optimize the capital and debt structure.
This is not the first time Li Zhenping has taken action. Just a few days ago, Blue Sail Medical disclosed two acquisitions—spending 800 million yuan to integrate the nitrile glove production capacity of its subsidiary, and spending 400 million yuan to buy 80% equity of a thermal power company from the actual controller. On one hand, the actual controller is lending money to the company, while on the other hand, the company is spending money to buy assets from the actual controller. Between the borrowing and the purchasing, Blue Sail Medical's situation has become clear; this glove leader, which has been losing money for four consecutive years, is undergoing a self-rescue that is cutting inward.
Regarding this issue, a reporter from Huaxia Times attempted to contact Blue Sail Medical for an interview but had not received a response by the time of publication.
Cash on Hand and Expiring Debt
First, let's look at some numbers.
The performance forecast for 2025 shows that Blue Sail Medical's net profit attributable to the parent company is expected to lose between 650 million and 850 million yuan, with a non-recurring loss of 780 million to 980 million yuan. Compared to the loss of 446 million yuan in 2024, the loss margin has not only failed to narrow but has further expanded.
<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OUzWQnqpmXQwIupTXJAdgEeQX67rxFgVU80K4RHIJ8de8AA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OUzWQnqpmXQwIupTXJAdgEeQX67rxFgVU80K4RHIJ8de8AA/641"/>
(Screenshot from the 2025 performance forecast)
The direct consequence of continuous losses is the ongoing depletion of cash on hand. As of the third quarter of 2025, the company's cash and cash equivalents amounted to only 1.357 billion yuan, and including trading financial assets, the total cash-like assets are only 2.2 billion yuan. Meanwhile, short-term debts have exceeded 4.4 billion yuan.
The debt structure is also not optimistic, with 1.52 billion yuan of convertible bonds maturing in two months, high foreign currency borrowings weighing down, plus a 1 billion yuan repurchase obligation hanging overhead. Just the &#34;non-current liabilities due within one year&#34; item surged from 1.283 billion yuan at the end of the first quarter to 4.025 billion yuan at the end of the third quarter. The current ratio is 0.9, and the quick ratio is 0.7, both falling below the warning line—debt repayment pressure is already a sword hanging overhead.
<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OJbYvaNlbeB7QpZ0HUB3P6B3jXb4RPsu2EEvHorxFJpdQAA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OJbYvaNlbeB7QpZ0HUB3P6B3jXb4RPsu2EEvHorxFJpdQAA/641"/>
(Screenshot from Wind)
Against this backdrop, on March 17, the conversion price of &#34;Blue Sail Convertible Bonds&#34; was adjusted downward to 7.95 yuan per share, marking the eighth downward adjustment since 2024. However, the adjustment space is extremely limited
According to regulations, the conversion price must not be lower than the latest audited net asset value per share, which is reported to be RMB 7.65 in the Q3 2025 report.
Since March, the stock price of BLUE SAIL MEDICAL has risen from around RMB 6 to about RMB 8, but the progress of conversion has not significantly improved. With only two months left until the convertible bonds mature, the repayment pressure of RMB 1.52 billion is ultimately unavoidable.
In addition, BLUE SAIL MEDICAL also faces significant tax payment pressure in 2025. The company's announcement indicates that, as required by the tax authorities, a special tax adjustment self-inspection will be conducted for the cross-border related party transactions and transfer pricing issues of the health protection division from 2020 to 2022. As of December 31, 2025, the company and its subsidiaries are required to pay back taxes and accrued interest totaling RMB 196 million. After deducting the amounts already prepaid and accrued, the remaining RMB 141 million will be included in the current profit and loss for 2025. For BLUE SAIL MEDICAL, which is burdened with over RMB 4 billion in short-term debt, this substantial tax payment undoubtedly exacerbates its cash flow pressure.
Under multiple pressures, the company has listed a series of countermeasures: introducing strategic investments, disposing of certain assets, issuing new debt... Among these, the first and most painful step is selling Wuhan Bikaier—the &#34;invisible champion&#34; that achieved the number one production capacity in the global first aid kit market.
On March 13, 2026, the company clearly stated in an investor relations event: through asset sales to realize cash, it will further focus on the two main businesses of health protection and cardiovascular health.
This means that the business segment that was once highly anticipated is being stripped from BLUE SAIL MEDICAL's strategic map.
From &#34;Spin-off Listing&#34; to &#34;Painful Sacrifice&#34;
The story of Wuhan Bikaier was once very promising.
In 2020, BLUE SAIL MEDICAL entered the first aid kit export market by acquiring Wuhan Bikaier. That was the tail end of the company's glory days—just that year, the price of PVC gloves skyrocketed, and BLUE SAIL MEDICAL's net profit attributable to the parent company surged to RMB 1.758 billion, a 2.5-fold increase year-on-year.
After the acquisition, BLUE SAIL MEDICAL continued to invest heavily. In November 2022, the company invested RMB 800 million in Tuanfeng County, Huanggang, Hubei, to build a project with an annual production capacity of 10 million first aid kits. The planning was ambitious, aiming to achieve annual sales of RMB 2 billion within 3-5 years and realize the goal of a spin-off listing under BLUE SAIL.
The investment indeed paid off in scale. As of now, the production capacity of first aid kits has reached 20 million sets per year, ranking first in the world, and the emergency rescue division has grown into an absolute leader in the niche market. In July 2025, BLUE SAIL Emergency Technology (Wuhan) Co., Ltd. was officially established, aiming to expand into the domestic emergency rescue market. At that time, the market was generally optimistic about the prospects of this segment.
However, just five months later, the reversal came unexpectedly.
On December 31, 2025, Mingde Bio announced its intention to acquire 100% equity of Wuhan Bikaier for cash. The transaction is expected to constitute a major asset restructuring. In February 2026, BLUE SAIL MEDICAL officially confirmed this strategic adjustment during an investor relations event
From the ambition of a spin-off listing to the reality of a full sale, only three years have passed.
The market is not surprised by this sale. At this point, BLUE SAIL MEDICAL has been losing money for four consecutive years, with a loss of 372 million yuan in 2022, 568 million yuan in 2023, and 446 million yuan in 2024. The projected loss for 2025 has expanded to between 650 million and 850 million yuan. Behind the losses are the combined effects of a sluggish main business and multiple pressures—tax arrears, fixed asset impairment, fluctuations in investment project valuations, and the financial costs of historical financing, each of which is draining the already tight cash flow.
<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OSxlmWuzlo9-tBu5yN_oL89sIvY_EiytsBgncdatYMddEAA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OSxlmWuzlo9-tBu5yN_oL89sIvY_EiytsBgncdatYMddEAA/641"/>
The issue of tax arrears is particularly tricky. This immediate cash outflow of 141 million yuan is akin to rubbing salt in the wound for a company burdened with over 4 billion yuan in short-term debt, further exacerbating liquidity tightness.
Selling Wuhan Bikaier is a way to stem the bleeding, but it is also a drastic measure. However, compared to the impending deadline of the betting agreement, this may just be an &#34;appetizer.&#34;
Countdown to the Betting Agreement
In addition to asset sales, BLUE SAIL MEDICAL faces a more urgent challenge: BLUE SAIL BAISHENG.
In 2024, its subsidiary Beijing Blue Sail Baisheng Medical Technology Co., Ltd. will introduce 1 billion yuan in strategic investment. Among them, the A1 round will see the Capital Health Industry Fund, Airport Private Equity Fund, and High-tech Industry Investment contributing a total of 900 million yuan for an 18.37% equity stake; at the same time, BLUE SAIL MEDICAL will convert its debt in BLUE SAIL BAISHENG into equity, with a post-investment valuation reaching 5.5 billion to 5.7 billion yuan. The A2 round introduced the Daxing Airport Development Fund, increasing its investment by 100 million yuan at a pre-investment valuation of 4.9 billion yuan, raising the post-investment valuation to between 5.6 billion and 5.8 billion yuan.
At that time, this financing was referred to as &#34;the second-largest private equity financing transaction in China's medical device sector in the past two years.&#34;
However, behind the glamorous financing lies a betting agreement: BLUE SAIL BAISHENG must achieve a public listing by September 30, 2026. If it fails to do so, the investors have the right to require BLUE SAIL MEDICAL to repurchase shares and pay an annualized return of 10%.
Now, with just over six months left until the betting deadline, there has been no substantial progress toward BLUE SAIL BAISHENG's listing. Due to the potential repurchase obligation being recognized as a financial liability at the consolidated level, BLUE SAIL MEDICAL will continue to accrue financial expenses of 100 million yuan in 2025. Although this amount does not involve cash outflow, it is a tangible loss on the financial statements.
As the countdown to the betting agreement continues, another, more immediate crisis looms: 1.52 billion yuan in convertible bonds will mature in two months. At this time, Li Zhenping's 350 million yuan loan has arrived.
Can this money solve the problem?
Renowned tax and finance expert Liu Zhigeng analyzed to the &#34;Hua Xia Times&#34; reporter that while this loan cannot solve the fundamental problem, its strategic intent is clear: &#34;In the short term, it alleviates public pressure and sends a signal of 'the actual controller backing it up.' This type of interest-free or low-interest loan from the actual controller, which does not require collateral, is essentially a form of low-cost trust endorsement, helping to stabilize the emotions of creditors, investors, and suppliers to avoid a run or a breakdown in the credit chain
From a medium-term perspective, in conjunction with the convertible bond adjustment, strive for a window for conversion. The most urgent risk for Blue Sail Medical is that the remaining balance of 1.52 billion yuan in convertible bonds will mature in May 2026. If the stock price continues to be sluggish and fails to facilitate conversion, the company will face immense cash repayment pressure. In the long term, to gain time for strategic adjustments, focus on the cardiovascular and cerebrovascular sectors. Blue Sail Medical is advancing a major strategic transformation: focusing on the two main businesses of cardiovascular and health protection, while divesting non-core assets such as emergency rescue. This loan essentially seeks to secure a valuable breathing space for this 'business slimming + structural optimization' transformation, avoiding the forced low-price sale of quality assets due to short-term liquidity exhaustion.
However, a temporary check cannot ultimately fill the short-term debt hole of over 4 billion yuan, nor can it change the fundamental situation of four consecutive years of losses, much less pause the countdown of the betting agreement. Selling Wuhan Bikaier can bring in cash, but it also means cutting off a business segment that was once number one globally.
&#34;The three major problems currently facing Blue Sail Medical are interlinked: tax supplementary payments exacerbate losses, worsening losses lead to liquidity issues, and liquidity crises force asset sales and shareholder bailouts. The actual controller's borrowing is a 'stopgap' measure, selling the emergency rescue business is a reluctant 'cutting losses' move, while tax issues are a long-term consequence of rampant growth. Whether the company can weather the storm depends on whether the health protection and cardiovascular sectors can quickly turn losses into profits, and whether the debt restructuring can proceed smoothly,&#34; said Bai Wenxi, vice chairman of the China Enterprise Capital Alliance, to our reporter.
From the perspective of the two main businesses, the health protection business was once the profit pillar of Blue Sail Medical but fell into losses in 2025 due to fluctuations in international trade policies and intensified industry competition. The good news is that in 2025, the company's cardiovascular division achieved annual revenue of 1.4 billion yuan, with a year-on-year growth rate exceeding 24%, and was able to turn losses into profits despite bearing the fair value of equity investments (the financing before the listing of Tongxin Medical caused a fair value change loss of 120 million yuan).
What Blue Sail Medical is experiencing is not an active transformation but a passive self-rescue. The ultimate outcome of this self-rescue depends on three variables: how much 'ammunition' can be regained from selling Bikaier, whether Blue Sail Baisheng can outperform the remaining six-month listing betting agreement, and when the sluggish glove market will recover

002382

511380

深转交债

The actual controller of BLUE SAIL MEDICAL, Li Zhenping, plans to lend the company 350 million yuan to optimize its capital and debt structure. The company recently disclosed two acquisitions, demonstrating its efforts for self-rescue. However, BLUE SAIL MEDICAL has reported losses for four consecutive years, and the performance forecast for 2025 indicates that the net profit loss will expand to between 650 million and 850 million yuan, with short-term debts exceeding 4.4 billion yuan, increasing repayment pressure. On March 17, the conversion price of BLUE SAIL MEDICAL's convertible bonds was adjusted down to 7.95 yuan per share, marking the eighth adjustment since 2024

Li Zhenping's 350 million yuan and Blue Sail Medical's "amputation" moment